a Other regimens were used by 5 or fewer participants following discontinuation of any study regimen. The average costs per day of these other regimens were $93.28, $76.78, and $69.48 for participants discontinuing RAL, ATV/r, and DRV/r regimens, respectively.
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a Other regimens were used by 5 or fewer participants following discontinuation of any study regimen. The average costs per day of these other regimens were $93.28, $76.78, and $69.48 for participants discontinuing RAL, ATV/r, and DRV/r regimens, respectively. • The ACTG 5257 clinical trial is a head-to-head study comparing the efficacy and tolerability of these treatments when used in combination with emtricitabine/tenofovir DF (FTC/TDF) (200 mg/300 mg once daily) among treatment-naive adults with HIV-1 infection in the United States (US).
• At 96 weeks of follow-up, the RAL regimen exhibited favorable efficacy and safety results compared with the ATV/r and DRV/r regimens.
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OBJECTIVE
• The objective of this study was to estimate the HIV treatment costs associated with the three antiretroviral regimens examined in the ACTG 5257 clinical trial for the US.
METHODS

Model Overview
• This cost analysis followed a cohort of treatment-naive individuals with HIV-1 infection in the US from baseline through 96 weeks as they progressed through treatment in the ACTG 5257 clinical trial.
• As individuals progressed, the model tracked the costs incurred and estimated per-person costs by category and in aggregate for each first-line regimen.
• The first-line regimens analyzed and the modeled cost outcomes for each are shown in Figure 1 . a Individuals who discontinued their study regimen in the model were transitioned to various substitution regimens based on the percentage of participants who switched to each regimen in the trial ( Figure 3 ). 1,2 The weighted average substitution regimen cost was calculated based on these percentages. a The pooled baseline characteristics of the intention-to-treat population from the ACTG 5257 clinical trial were used to establish the distribution of the modeled cohort across health states at treatment initiation. The intention-to-treat population received RAL (n = 603), ATV/r (n = 605), or DRV/r (n = 601).
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LIMITATIONS
• This analysis was limited to the first-line regimens included in the ACTG 5257 clinical trial and did not incorporate other common first-line regimens.
• Since clinical trial participants typically achieve very high levels of adherence, the modeled efficacy results may be better than those observed in real-world clinical practice.
• Cost outcomes were estimated through 96 weeks only; potential long-term benefits of RAL were not captured.
• Adverse event and HIV care cost data were somewhat dated but were the most recent available.
DISCUSSION AND CONCLUSIONS
• RAL has the lowest total per-person 96-week cost when compared with ATV/r and DRV/r for treatment-naive adults with HIV-1 infection in the US.
• These results were found to be robust in sensitivity and scenario analyses.
• This economic evidence complements the known clinical benefits of RAL as reported in the ACTG 5257 clinical trial.
• RAL had the lowest per-person total cost after 96 weeks of treatment compared with DRV/r and ATV/r when each was used in combination with FTC/TDF ( Figure 4 ).
• Model results were robust in scenario and sensitivity analysis.
-RAL had the lowest per-person total cost in all scenarios tested (alternate trial endpoint for regimen discontinuation, shorter time horizon, no discounting, without adverse event costs, without HIV care costs).
-100% of probabilistic sensitivity analysis (PSA) runs found RAL to have the lowest total per-person cost ( Figure 5 ).
-ATV/r had the widest variability in per-person total costs due to the high incidence of hepatobiliary investigation events and the substantial uncertainty in the associated cost per event ( Figure 5 ).
-The 95% confidence interval for the total per-person cost for RAL in the PSA did not overlap with the confidence interval for either of the two comparator regimens ( Figure 5 ).
Input Parameters
• Baseline characteristics for the modeled cohort were taken from the ACTG 5257 clinical trial (Table 1) .
• Efficacy and tolerability data were taken from the ACTG 5257 clinical trial 1,2 to transition the modeled cohort between CD4 cellcount ranges and to alternative regimens after first-line regimen discontinuation (Figure 2 ).
• Total daily regimen costs for each comparator first-line regimen and substitution regimen were based on wholesale acquisition costs (Table 2, Figure 3 ).
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• Grade 3 or 4 adverse events with an incidence of at least 2% in any arm of the ACTG 5257 clinical trial were included. 1, 2 The model applied a per-episode cost 4 and assumed the cost was incurred within the first 48 weeks of treatment (Table 3 ).
• HIV care costs included costs for disease monitoring and the treatment and prevention of opportunistic and other infections (Table 4) . 
